ALLO News and Press, Allogene Therapeutics Inc. From 06/30/21

Allogene Therapeutics (ALLO) perks up 5% premarket after announcing that the FDA has granted Fast Track designation to ALLO-605, the next-generation AlloCAR T therapy targeting BCMA for the treatment of relapsed or refractory multiple myeloma.Fast Track status provides for...

Phase 1 IGNITE Dose Escalation Trial of ALLO-605 Initiated in Q2 2021 ALLO-605 is the Third Prong of the Company’s Clinical Strategy to Target BCMA for the Treatment of Multiple Myeloma TurboCAR TM Technology Provides Selective, Programmable Cytokine Signaling Designe...

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at $23.16, breaking its 52-week low. This new low was reached on below average trading volume as 254,000 shares traded hands, while the average 30-day volume is approximately 1.7 million shares. Allogene Therapeutics Inc is ...

With the newly-announced leadership change, Allogene Therapeutics ([[ALLO]] +3.8%) is trading higher while Jefferies assumes coverage of the stock with a buy rating. The price target of $53.00 per share implies a premium of ~116.5% to the last close.Despite recent underperformance of Allogene...

koto_feja/E+ via Getty Images Allogene Overland Biopharm, a joint venture created by Overland Pharmaceuticals and Allogene Therapeutics (ALLO) , has appointed Dr. Shuyuan Yao as Chief Executive Officer. Dr. Yao brings 15 years of scientific and management experience in advanced cell and ...

Veteran pharmaceutical executive with proven cell and gene therapy development experience in Asia, formerly of WuXi AppTec Shanghai and the joint venture JW Therapeutics Allogene Overland Biopharm (Allogene Overland), a joint venture created by Overland Pharmaceuticals a...

Allogene is a leading allogeneic CART developer. It is slowly delivering strong data for its programs. The company is well-funded. For further details see: Allogene: Continuing To Deliver Solid Data In Allogeneic CART

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at $23.31, breaking its 52-week low. So far today approximately 254,000 shares have been exchanged, as compared to an average 30-day volume of 1.6 million shares. In the past 52 weeks, shares of Allogene Therapeutics Inc. ha...

Shares of Allogene Therapeutics Inc. (NASDAQ:ALLO) traded today at $23.87, breaking its 52-week low. Approximately 254,000 shares have changed hands today, as compared to an average 30-day volume of 1.6 million shares. Allogene Therapeutics Inc is a United States-based clinical stage imm...

ASCO Posters Detail Results from ALLO-501 ALPHA and ALLO-501A ALPHA2 Trials in Non-Hodgkin Lymphoma and Safety and PK/PD Data of ALLO-647 with Flu/Cy Across the ALPHA, ALPHA2 and UNIVERSAL Studies Results from Most Recent Data Discussed at Allogene’s CD19 Forum Demonstrate...